

Diagnosis of neoplasia in a kidney transplant unit

J. Kanter, L.M. Pallardó, J.F. Crespo, E. Gavela, S. Beltrán, A. Ávila, A. Sancho

Department of Nephrology. Dr. Peset University Hospital. Valencia, Spain

Nefrología 2009;29(4):311-317.

ABSTRACT

Background and aim: Cancer is one of the major causes of death with functioning allograft among renal transplant patients. The increasing age of patients in the waiting list has derived in a higher risk of cancer in this population. The aim of this study was to analyze the incidence of cancer in the waiting list and kidney transplant patients. **Methods:** Between November/1996 and November/2007 we assisted 825 patients in the outpatient renal transplant clinic, 467 were transplanted, 120 remained in the waiting list and 238 have been removed from the waiting list or died. **Results:** During this period, 97 malignancies were diagnosed, 33 of 32 kidney transplant candidates and 64 of 62 renal transplant patients. The comparative analysis between this two groups showed that candidates had higher frequency of solid organ tumours compared with a higher incidence of skin cancer in transplanted patients. Mean time between transplant and cancer diagnosis was 42.6 ± 32.7 months, 48% of malignancies were diagnosed within the first three years posttransplant. When comparing kidney transplant patients with and without cancer diagnosis, the formers were older and had worse patient survival at five years. Allograft survival was similar for both groups. **Conclusions:** we want to emphasize the extreme importance of a detailed screening in the renal transplant candidates and transplanted patients due to a higher incidence of malignancies in this population.

Key words: Cancer. Kidney transplant. Waiting list. Screening.

RESUMEN

Introducción y objetivo: El cáncer es una de las principales causas de muerte con injerto funcionando en los pacientes trasplantados renales. La creciente edad de los pacientes remitidos para su inclusión en lista de espera ha elevado el riesgo de neoplasias en esta población. El objetivo de este estudio fue analizar la incidencia de neoplasias en los pacientes evaluados para su inclusión en lista de espera para trasplante y en los trasplantados renales. **Métodos:** Entre noviembre de 1996 y noviembre de 2007 fueron evaluados 825 pacientes en la consulta de trasplante renal; 467 habían recibido un injerto renal, 120 permanecían en lista de espera y 238 habían sido desestimados o fallecieron estando en lista de espera. **Resultados:** Se diagnosticaron 97 tumores, 33 de ellos en 32 pacientes candidatos a trasplante y 64 tumores en 62 pacientes trasplantados. El análisis comparativo entre los pacientes candidatos (incluidos o no en lista de espera) y aquellos trasplantados mostró que los primeros presentaron con mayor frecuencia tumores sólidos, mientras que los segundos presentaron mayor porcentaje de neoplasias cutáneas. La incidencia de tumores sólidos en la población trasplantada fue del 5,6%. El tiempo entre la fecha de trasplante y el diagnóstico del tumor fue de $42,6 \pm 32,7$ meses, siendo el 48% de las neoplasias diagnosticadas en los primeros tres años posttrasplante. Al analizar pacientes trasplantados con y sin diagnóstico de neoplasias, observamos que los primeros tenían mayor edad y un mayor seguimiento posttrasplante. La supervivencia del injerto fue similar entre ambos grupos, siendo la supervivencia del paciente a los cinco años significativamente menor en el grupo de pacientes trasplantados con tumor. **Conclusiones:** La notable incidencia de tumores pre y posttrasplante enfatiza la necesidad de una búsqueda y un seguimiento exhaustivos de tumores en los pacientes trasplantados y una alta sospecha en la valoración pretrasplante.

Palabras clave: Neoplasias. Trasplante renal. Lista de espera. Valoración pretrasplante.

INTRODUCTION

Cancer is one of the main causes of death in kidney transplant patients with a functioning graft, and it is thought that it could overtake cardiovascular as the main cause of death in the next two decades.¹ Although the introduction of

Correspondence: Julia Kanter Berga
Servicio de Nefrología.
Hospital universitario Dr. Peset. Valencia.
jkanter@senefro.org

new immunosuppressant agents has resulted in a decrease in acute rejection rates there has been an increase in the number of long-term complications, such as neoplasias.² Furthermore, the mean age of transplant recipients and patients referred for assessment for inclusion in the kidney transplant waiting list has increased by 10 years in just a decade.³

As in the general population, the main risk factors for developing neoplasms in the population with chronic kidney disease (CKD) are advanced age, male sex, and exposure to carcinogenic agents such as tobacco, alcohol and sunlight.^{4,5} Specific, risk factors in CKD include malnutrition, metabolic changes, prolonged time on dialysis, retention of carcinogenic compounds, the aetiology of kidney failure and its treatment, and uraemic immune deficiency.⁶ Following a kidney transplant, there is the added risk of the immunosuppressive treatment^{7,8} and the reactivation of potentially oncogenic viruses, such as Epstein-Barr, herpes virus type 8, human papillomavirus, hepatitis B and C viruses, and a higher risk of developing skin cancer, non-Hodgkin's lymphoma and Kaposi's sarcoma.⁹ A study based on the joint registry data from Australia and New Zealand (ANZData) comparing the neoplasia incidence rate in 28,855 patients with CKD who were on dialysis or transplanted showed that the risk of developing 18 different kinds of neoplasms was 3-fold.¹⁰

The development of cancer following kidney transplantation could be due to: *de novo* post-transplant malignancy, transfer of tumours inadvertently from the donor or recurring/pre-existing neoplasms in the recipient that may not have been detected during pre-transplant screening.¹¹ The advanced age of potential kidney transplant recipients not only increases the risk of developing *de novo* post-transplant neoplasms, but also the probability of having occult malignancy prior to transplantation. In this context, the aim of this study was to

determine the incidence rate of neoplasias in the population referred to a kidney transplant unit, including those patients awaiting kidney transplantation and those having already undergone a kidney transplant.

DESIGN OF THE STUDY

Retrospective and observational study carried out in the kidney transplant unit in our hospital over an 11-year period (November 1996-November 2007).

PATIENTS AND METHODS

The population covered by our transplant unit consists of about a million inhabitants. During the study, approximately 825 patients were evaluated in the kidney transplant unit. On average, 75 patients/year are sent to our unit to be evaluated for transplantation, out of which approximately 60 patients/year are included on the waiting list for kidney transplantation. The remaining patients are deemed unsuitable for transplantation or referred to another centre (kidney-pancreas transplant). The general criteria for referring patients who are diagnosed with chronic renal failure and apt for receiving a transplant include: age < 75 years except in certain circumstances, life expectancy > 2 years and absence of serious illnesses (advanced chronic liver disease, chronic respiratory failure, untreatable heart disease or active infectious disease, recent or metastatic neoplasia or severe psychiatric disorders).

CKD patients on dialysis were assessed according to a standard protocol at their respective centres to determine their suitability for kidney transplantation using preliminary imaging and laboratory tests before referral to the kidney transplant division. This protocol included

Table 1. Tests for neoplasia detection

Procedure	Initial age (years)	Interval	
		Waiting list	Transplant
Abdominal ultrasound/Doppler echo	Any	5 years	1 year
Chest X-rays	Any	1 year	-
PSA	>50	1 year	1 year
Mammogram	>40	2 years	2 years
Barium enema	>50	Baseline	5 years
Faecal occult blood	>50	-	1 year
Dermatological screening	Any	Baseline	1 year
Gynaecological screening	>40	2 years	2 years
Bone series	Any	5 years	-

PSA: prostate-specific antigen. .

specific examinations designed to rule out the presence of neoplasias, as well as interval at which the tests need to be repeated (table 1).

We do not know the number of patients turned down for transplantation due to a tumour being detected by the referring haemodialysis unit, nor do we have information on the tumour types. However, we do have data on those patients in whom the neoplasia was diagnosed when they were already on the transplant waiting list.

At the end of the study, 467 patients had received a kidney transplant, 120 were still on the transplant waiting list and 238 patients had been excluded or had died while waiting for a transplant. 102 patients lost the graft, and 30 received a second transplant.

We collected data from all potential kidney transplant recipients (whether or not they were on the waiting list) and those already transplanted who had been diagnosed with a tumour and compared them with the patients who had not developed a neoplasm. The following variables were analysed: age, sex, body mass index (BMI), CKD aetiology, time on dialysis, personal history of cancer, immunotherapy treatment, tumour type, time between the transplant date and diagnosis of the tumour, smoking history and viral serology.

STATISTICS

Values are expressed as percentage, mean and standard deviation, range and 95% confidence interval. The Chi-square test or Fisher's exact test were used as appropriate for comparing categorical variables. The differences between the means were analysed using analysis of variance (ANOVA). Values of $p < 0.05$ were considered to be statistically significant. The survival analysis was carried out by the Kaplan-Meier method and the Log-rank test. Data was analysed using SPSS statistical software, version 15.

RESULTS

In a period of 11 years, 97 tumours were diagnosed in 825 patients followed up in the kidney transplant division. A total of 33 tumours were diagnosed in 32 potential transplant recipients: 17 tumours were detected during the evaluation process, and the affected patients were not included on the transplant waiting list (6 prostate, 2 bladder, 3 kidney, 2 larynx and 2 colon tumours, as well as 1 multiple myeloma and 1 basal cell carcinoma excluded due to cardiovascular risk); the other 16 tumours did not contraindicate transplantation. Of this last group, 8 received a transplant (5 had basal cell carcinomas, 2 squamous cell carcinomas and 1 rectal neoplasia after a five-year follow up period).

The 467 transplanted patients were followed up for a mean of 79 ± 34 months (range 8-132) from the transplant date; 62 patients were diagnosed with 64 *de novo* tumours, representing a neoplasia incidence of 13.2%.

The characteristics of the potential transplant recipients and the transplant patients diagnosed with neoplasias are similar. The two groups mean age was 59 years and they were, predominantly male. There were no differences in CKD aetiology, BMI, viral serology (VHC, CMV, Epstein-Barr or varicella zoster). There was a larger number of smokers in the group of potential kidney transplant recipients that had a diagnosis of neoplasias (68 vs. 40%, $p = 0.02$) (table 2). For this group, the mean time between starting renal replacement therapy and the diagnosis of neoplasia was 30.8 ± 44 months. For the transplant group, the mean time between the transplant date and the diagnosis of the tumour was 42.6 ± 32.7 months (95% CI 34-51 months, range 2-124). In these patients, 48% of the neoplasias were diagnosed in the first three years after transplantation, particularly skin neoplasms (figure 1). In the potential transplant recipient group, solid tumours were diagnosed more frequently than in the transplant group (70.6 vs. 47.6%, $p = 0.03$), while in the transplant group, cutaneous neoplasias were more common (52.4 vs. 29.4%, $p = 0.03$). Solid neoplasias in possible transplant candidate patients were predominantly located in the following areas: genitourinary (7 prostate, 3 kidney, 2 bladder), gastrointestinal tract (2 colon, 1 rectal, 1 stomach) and larynx (3 cases). Among transplant patients, the most common solid neoplasia was renal cell carcinoma (6 cases) (table 3). The incidence of solid tumours in the transplant population was 5.6%.

Comparative analysis of the transplant population between those who developed tumours and those who did not showed that the former were older (55 ± 10 vs. 49.6 ± 13 years, $p = 0.000$) and were more likely to have received ciclosporin rather than tacrolimus as initial immunosuppressor treatment (CSA 71 vs. 53%, $p = 0.006$). Patients diagnosed with neoplasias had a longer post-transplant follow-up (89.4 ± 33 vs. 77.1 ± 34 months, $p = 0.007$). We found no significant differences when comparing by gender, smoking history prior to transplantation, time on dialysis, anti-lymphocyte induction, presence of acute tubular necrosis post-transplant and the number of episodes of acute rejection that were treated (table 4).

Five year graft survival was similar for both groups (93.2% for transplant patients with a tumour vs. 95.2% for patients with no tumours, $p = 0.4$). However, patient survival at five years was significantly less in the group of transplant patients with tumours (93.2 vs. 98.8%, log-rank = 5.69, $p = 0.017$) (figure 2). Ten of the eleven transplant patients died because of the tumour (table 5).

Table 2. Epidemiological characteristics of kidney transplant patients and potential transplant recipients diagnosed with neoplasia

	Potential recipients with neoplasia n = 32	Transplant patients with neoplasia n = 62	p
Age (years)	59 ± 7	59 ± 10	0,9
Male (%)	67,6	65.6	0,8
Aetiology of CKD (%)	CGN 31.8 NUNK 22.7 PKD 13.6	GNC 27.1 NUNK 30.5 PKD 11.9	0,7
BMI	25 ± 4	25 ± 4	0,7
HCV + (%)	9.5	10.5	0,25
CMV+ IgG(%)	100	87.5	0,17
IgG+ Epstein Barr (%)	77.8	75.8	0,9
IgG+ VZV (%)	90	89	0,9
Smoker (%)	68	40	0,02

CKD: chronic kidney disease; CGN: chronic glomerulonephritis; NUNK: nephropathy of an unknown cause; PKD: polycystic kidney disease; BMI: body mass index; HCV +: hepatitis C positive. IgG CMV+: IgG positive for cytomegalovirus. IgG VZV+: IgG positive for varicella zoster

DISCUSSION

Neoplasia is prevalent in both the population on dialysis and in kidney transplant recipients.¹² In the latter group, neoplasia is one of the main causes of death and could become the leading cause. In the present study, we

determined the frequency of neoplasms in our kidney transplant unit, in both the possible candidates for renal transplantation and the kidney transplant recipients.

A significant aspect of our series was the high number of neoplasias diagnosed during the patient’s evaluation process




Figure 1. Percentage of neoplasms diagnosed after the transplant.

Table 3. Tumour type by group

Tumour type	Neoplasms in Potential recipients n = 33 (%)	Neoplasms in transplant patients n = 64 (%)
SKIN	11	33
Basal cell carcinoma	8 (24)	23 (36)
Squamous carcinoma	3 (9)	8 (12,5)
Kaposi's sarcoma	0	1 (1,6)
Melanoma	0	1 (1,6)
Lymphoma/syndrome		
Lymphoproliferative	0	4 (6)
URINARY	12	12
Prostate	7 (21)	2 (3)
Bladder	2 (6)	4 (6)
Kidney	3 (9)	6 (9)
OTHER	10	15
Digestive tract	4 (12)	4 (6)
Lung	0	4 (6)
Larynx	3 (9)	1 (1,6)
Uterine/ovarian	0	2 (3)
Breast	1 (3)	4 (6)
Thyroid	1 (3)	0
Multiple myeloma	1 (3)	0

for inclusion on the waiting list and on patients on the waiting list for a kidney transplant. We feel that this issue has not been stressed enough in the literature and that it may be increasingly relevant due to the increase in age of this population. It is important to note that the population of potential transplant recipients in our study may not be representative of the general population on dialysis, given that in some cases neoplasias were

diagnosed in the patient's referral centre and these patients were not referred to the transplant unit and no information was given in this regard to the transplant centre. We would like to point out the importance of the work carried out by the urologists who evaluate these patients in their weekly clinics, a fact that may explain the high incidence of prostate tumours diagnosed in possible potential transplant recipients.

Table 4. Epidemiological characteristics of transplant patients with positive or negative diagnosis of neoplasia

	Transplant patients with neoplasia n = 62	Transplant patients without neoplasia n = 405	p
Age (years)	55 ± 10	49.6 ± 13	0.000
Male patients (%)	63.5	53.7	0.15
Smoker prior to transplant (%)	41.8	41	0.9
Months on dialysis	53 ± 54	43.3 ± 41	0.1
Induction therapy with globulins (%)	36	31	0.4
No. HLA mismatches	3.3 ± 1	3.2 ± 1	0.4
Post-transplant ATN (%)	45.5	47	0.8
Initial immunosuppressant (%)			
CSA vs. TAC 71 vs	71 vs. 29	53 vs. 47	0.006
Acute rejection (%)	14.3	21.1	0.19
Post-transplant follow-up (months)	89.4 ± 33	77.1 ± 34	0.007

ATN: acute tubular necrosis; CSA: ciclosporin; TAC: tacrolimus.




Figure 2. Transplant patient survival according to positive or negative diagnosis of neoplasia.

For the first three years following the transplant, the high incidence of tumours is similar to that of the patients being evaluated for transplantation suggesting the pre-existence of risk factors that could worsen with the immunosuppressive therapy. Our findings show that apart from the well recognised neoplasms of the transplant population (cutaneous and lymphoproliferative disorders), the most common solid tumours with the worse prognostic impact are similar in both populations, the genitourinary tract. These findings should give an idea of what examinations must be carried out frequently for early diagnosis of neoplasias in these patients. In our experience renal ultrasound and PSA testing proved particularly useful. In contrast, testing for FOB (faecal occult blood) has not been shown to be very sensitive,¹³ since four patients diagnosed with colon cancer in our study had previously had a negative test result. In this high-risk population, the screening should include periodic rectosigmoidoscopy in patients older than 50, following the

criteria recommended by scientific societies.^{14,15} The use of a barium enema is particularly useful in older patients with a high number of diverticula and a risk of post-transplant perforation.¹⁶

Skin tumours were more prevalent among the transplant patient group, and we observed a higher incidence of basal cell carcinoma than squamous cell carcinoma, contrary to what is published in the literature.¹⁷ This could be explained by better detection of this type of lesion in dermatology check-ups or due to the patients' advanced age or post-transplant follow up period. Initial treatment with ciclosporin was associated with a higher frequency of neoplasias in this group, as has been previously reported.^{17,18} In our study, we cannot discard the possibility that this was skewed by having a longer post-transplant follow-up for patients on ciclosporin than for those treated with tacrolimus. Also worthy of mention is the low frequency of lymphoproliferative disorders and Kaposi's sarcoma observed in the transplant patients, particularly when the former have been related to the use of anti-lymphocyte globulin (31% of our patients received induction therapy with thymoglobulin although doses were low). We could speculate on the protective effect of widely used ganciclovir-valganciclovir prophylaxis for CMV-related disease during the three first months following the transplant, although longer follow-up is needed in order to prove this hypothesis.

The incidence of de novo neoplasms in the transplant group is significantly higher than that in the general population, and the prognosis in the former group is also worse.¹⁹ Using US Registry data on 35,765 transplants, Kasiske showed that compared with the general population, neoplasia rates post-transplantation were 2-fold higher for the colon, lung, prostate and breast and 3-fold higher for bladder and testes. Melanoma, leukaemia and cervical neoplasms are 5-fold commoner in transplant recipients. The rates for kidney cancer are 15-fold and for Kaposi's sarcoma, non-Hodgkin's lymphomas and non-melanoma skin cancers the rates are over 20-fold more common.²⁰ An Italian study of 3,500 transplant patients demonstrated that the 10-year patient

Table 5. Causes of death in transplant patients

Death	Transplant, with tumour n = 62 (%)	Transplant, no tumours n = 405 (%)
NO	53 (83)	376 (92.8)
YES	11 (17)	29 (7)
Causes of death		
Tumour	10	0
Infection	1	11
Cardiovascular	0	14
Liver failure	0	2
Other	0	2

survival rate was 92.8% for transplant patients without tumours and 56.6% for those with neoplasia of any type.²¹ ANZData registry data showed that 67% of deaths in transplant patients with tumours were caused by the neoplasia.¹¹

Our findings suggest that the prevention of neoplasias post-transplantation should be based on proper examination of the transplant candidate population, including periodic check-ups while patients remain on the waiting list. After a patient receives a kidney transplant, we should reach a delicate balance between the immunosuppression and the immunological risk, identifying those patients who might benefit from early conversion to proliferation signal inhibitors.

Initial treatment with or conversion to this drug group appears to be followed by lower rates of neoplasia, and it has been shown to be effective for treating patients with certain tumours, particularly skin tumours and Kaposi's sarcoma.²²

REFERENCES

- Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. *Transplantation* 2005;80(2):S254-64.
- Bosmans JL, Verpooten GA. Malignancy after kidney transplantation: Still a Challenge. *Kidney Int* 2007;71(12):1197-9.
- Gaston RS, Alveranga DY, Becker BN, et al. Kidney and pancreas transplantation. *Am J Transplant* 2003;3(4):64.
- Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. *Transplantation* 1999;68:1859-64
- Ramsay HM, Fryer AA, Hawley CM, Smith AG, Nicol DL, Harden PN. Factors associated with non-melanoma skin cancer following renal transplantation in Queensland, Australia. *J Am Acad Dermatol* 2003;49:397-406.
- Gutiérrez-Dalmau A, Campistol JM. Immunosuppressive therapy and malignancy in organ transplant recipients: a systematic review. *Drugs* 2007;67(8):1167-98.
- Opelz G and Henderson R. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients. *Lancet* 1993;342:1514-6.
- Dantal J, Pohanka E. Malignancies in renal transplantation: an unmet medical need. *Nephrol Dial Transplant* 2007;22(1):4-10.
- Morath C, Mueller M, Goldschmidt H, Schwenger V, Opelz G, Zeier M. Malignancy in renal transplantation. *J Am Soc Nephrol* 2004;15:1582-88.
- Vajdic CM, McDonald SP, McCredie MRE, et al. Cancer incidence before and after kidney transplantation. *JAMA* 2006;296(23):2823-31.
- Kauffman HM. Malignancies in Organ Transplant Recipients. *Journal of Surgical Oncology* 2006;94:431-33.
- Andres A. Cancer incidence after immunosuppressive treatment following kidney transplantation. *Crit Rev Oncol Hematol* 2005;56(1):71-85.
- Loitsch SM, Shastri Y, Stein J. Stool test for colorectal screening, it's time to move. *Clin Lab* 2008;54(11-12):473-84.
- U.S. Preventive Services Task Force. Screening for Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement. *Annals of Internal Medicine* 2008;149(9):e-pub ahead of print.
- Bond JH. Fecal occult blood test screening for colorectal cancer. *Gastrointest Endosc Clin N Am* 2002;12(1):11-21.
- González-Posada JM, Grupo De Estudio Forum Renal, Arias M, et al. Documento de consenso "Trasplante renal en pacientes de edad avanzada con un riñón de donante añoso". *Nefrología* 1998;18(5):38-44.
- Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. *NEJM* 2003;348:1681-91.
- Kauffman HM, Cherikh WS, McBride MA, et al. Post transplant de novo malignancies in renal transplant recipients: The past and the present. *Transplant Int* 2006;19:607-20.
- EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. *Nephrol Dial Transplant* 2002;17(4):32,34-6.
- Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. *Am J Transplant* 2004;4:905-13.
- Pedotti P, Cardillo M, Rossini G, et al. Incidence of cancer after kidney transplant: Results from the North Italy Transplant Program. *Transplantation* 2003;76:1448-51.
- Stallone G, Infante B, Grandaliano G, Schena FP, Gesualdo L. Kaposi's sarcoma and mTOR: a crossroad between viral infection neoangiogenesis and immunosuppression. *Transplant Int* 2008;21(9):825-32.